Skip to main content

The 2024 Symposium on Public Health Strategies for Combating Substandard and Falsified Drugs

Public-Facing Webinars and Symposiums
Tuesday, November 12, 2024, 8:00 a.m. - Wednesday, November 13, 2024, 4:30 p.m. ET
Location
Hopkins Bloomberg Center in DC
Onsite
Add to Calendar 15 jhu-bsph-308881 The 2024 Symposium on Public Health Strategies for Combating Substandard and Falsified Drugs

Join the 2024 Symposium on Public Health Strategies to Combat Substandard & Falsified Drugs, Nov 12-13, DC. Free registration; limited seats!



For more information, visit the event page:
https://publichealth.jhu.edu/node/308881.

Johns Hopkins Bloomberg School of Public Health
2024-11-12 13:00 2024-11-13 21:30 UTC use-title Location Hopkins Bloomberg Center in DC

Description

The 2024 Symposium on Public Health Strategies for Combating Substandard and Falsified Drugs, hosted by Johns Hopkins Bloomberg School of Public Health, will bring together global leaders, policymakers,  public health researchers, regulatory agencies, and other key practitioners to address the critical issue of substandard and falsified drugs affecting public health worldwide.

The global health burden of substandard and falsified (SF) drugs is alarming and rapidly growing, especially with the high number of online pharmacies currently estimated at around 35,000, of which 95% are unlicensed. This issue affects nearly all areas, particularly oncology, mental health, chronic diseases, HIV, infectious diseases, and weight management. While the issue of SF drugs is thought to be a problem of lower- and middle-income countries, a recent survey found that in the U.S., more than 38% of Americans have been directly or indirectly exposed to events in which someone had received a substandard or falsified prescription medication from an online pharmacy. The current reports are concerning, and they require urgent public health attention.

For example:

  • In oncology, SF drugs contribute to treatment failures, increasing mortality, with estimates indicating that 10–30% of cancer drugs in low- and middle-income countries are substandard or falsified.
  • In reproductive, maternal, newborn, and child health, in some countries more than 70% of oxytocin on the market is substandard or falsified, contributing to high maternal and child mortality.
  • Chronic disease medications, including antihypertensives and diabetes drugs, face similar threats, compromising the health of over 300 million patients globally.
  • In the U.S., an unauthorized network of drug distributors and suppliers sold over $250 million worth of counterfeit versions of HIV treatments, endangering patients and worsening the crisis. Globally, 19% of HIV drugs in some African regions have been found to be substandard, exacerbating drug resistance and disease spread.
  • Infectious diseases like malaria are severely impacted, with over 72,000–267,000 deaths annually in sub-Saharan Africa linked to falsified antimalarials.
  • The rise of online pharmacies has further exacerbated the problem, facilitating access to these dangerous products globally, with an estimated 50–90% of medicines sold online being fake or substandard.
  • In the U.S., counterfeit drugs containing fentanyl have fueled the opioid crisis, having caused more than 100,000 deaths in 2022, contributing to over 80% of opioid overdose deaths.

    Registration

  • Registration is required
  • Please register in advance

Contact Info

EISHITA PAL